 |
|
|
| |
Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 497 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting)
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
C Hezode1, C Dorival2, F Zoulim3, D Larrey4, S Pol5, P Cacoub6, V Canva7, T Poynard8, D Samuel9, M Bourliere10, L Alric11, JJ Raabe12, JP Zarski13, G Riachi14, PH Bernard15, V de Ledinghen16, V Loustaud-Ratti17, S Metivier18, X Causse19, P Marcellin20, Y Barthe2, H Fontaine5, F Carrat2, JP Bronowicki21 for the CUPIC study group (ANRS CO 20)
Hopital Henri Mondor, Creteil, 2. UMR-S 707, Paris, 3. INSERM U871, Lyon, 4. Hopital Saint-Eloi, Montpellier, 5. Hopital Cochin, Paris, 6. Medecine interne, Hopital de la Pitie-Salpetriere, Paris, 7. Hopital Claude Huriez, Lille, 8. Hepatologie, Hopital de la Pitie-Salpetriere, Paris, 9. Hopital Paul Brousse, Villejuif, 10. Fondation Hopital Saint Joseph, Marseille, 11. Medecine interne, Hopital Purpan, Toulouse, 12. Hopital Bon Secours, Metz-Thionville, 13. Hopital Albert Michallon, Grenoble, 14. Hopital Charles Nicolle, Rouen, 15. Hopital Saint Andre, Bordeaux, France. 16. Hopital Haut Leveque, Bordeaux, 17. Hopital Dupuytren, Limoges, 18. Hepatologie, Hopital Purpan, Toulouse, 19. Hopital de La Source, Orleans, 20. Hopital Beaujon, Beaujon, 21. Hopital de Brabois, Nancy, France.
|
| |
|
|
|
|
|
